NOVAVAX to Present at 13th Annual BIO CEO & Investor Conference
ROCKVILLE, Md., Feb. 10, 2011 /PRNewswire via COMTEX/ --
Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced today that Dr. Rahul Singhvi, President and Chief Executive Officer of Novavax will be presenting at the 13th Annual BIO CEO & Investor Conference on February 15th, 2011 at 11:00 am local time. Hosted by the Biotechnology Industry Organization (BIO), the 13th Annual BIO CEO & Investor Conference will take place February 14-15 at the Waldorf Astoria hotel, New York. Dr. Singhvi will provide an overview of the company's business strategy, research and development progress and upcoming milestones. A link to the live audio only presentation can be accessed via the Company website at www.novavax.com under the Investors tab. An archive of the presentation will be available one hour after the event on the Novavax website for 90 days.
Novavax, Inc. (Nasdaq: NVAX), a clinical-stage biopharmaceutical company, employs it's cutting edge technology to create next generation vaccines to prevent serious infectious diseases, such as pandemic and seasonal influenza and respiratory syncytial virus (RSV). The company's proprietary virus-like particles (VLPs) technology and unique disposable system enables rapid vaccine development and production where and when it's needed, worldwide. For more information about Novavax, please visit www.novavax.com.
SOURCE Novavax, Inc.